Understanding Genetic Factors for Semaglutide Response in Prediabetes

Glucagon-like peptide-1 (GLP-1) is a vital hormone known for its roles in glucose reduction, weight loss, and protecting against cardiovascular and renal diseases. Prediabetes is a widespread condition that significantly increases the risk of developing type 2 diabetes, obesity, and other metabolic disorders. Despite the known benefits of GLP-1 agonists like Semaglutide, individual responses can vary significantly, and the underlying genetic and transcriptomic mechanisms driving these differences are not fully understood.

As this is a recruiting study with an estimated completion date of October 31, 2026, specific results are not yet available. However, the project aims to identify novel genetic and transcriptomic markers that predict individual responses to Semaglutide in Mexican-Americans with prediabetes. The study anticipates revealing causal links between specific disease genotypes and phenotypes, potentially explaining variations in glucose reduction, weight loss, and improvements in cardiovascular and renal risk factors. The most important anticipated finding is the identification of specific genetic profiles that correlate with stronger or weaker responses to GLP-1 therapy, providing a basis for personalized treatment.